Nurulamin M Noor

Dr. Nurulamin M Noor

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2021 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
GCGlobal Burden of Disease 2019 Cancer Collaboration
Global Burden of Disease 2019 Cancer Collaboration
JKJonathan M. Kocarnik
Jonathan M. Kocarnik
KCKelly Compton
Kelly Compton
FDFrances E. Dean
Frances E. Dean
WFWeijia Fu
Weijia Fu
LFLisa M. Force
Lisa M. Force
Cancers are a major contributor to disease burden worldwide, and projections forecast that global cancer burden will continue to grow for at least the next 2 decades.1-4 The United Nations (UN) Sustainable Development Goals (SDGs) recognize the need for reducing cancer burden as part of target 3.4, stating “By 2030, reduce by one third premature mortality from noncommunicable diseases [NCDs] through prevention and treatment and promote mental health and well-being.”5 Most countries will need to accelerate their efforts to reduce NCD burden, including cancer, to meet this SDG target.6,7 Increasing the pace of progress will be particularly critical given the ongoing COVID-19 pandemic, which has led to delays and disruptions in cancer screenings, diagnosis, and treatment around the world.8-12

12 October 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
TRTim Raine
Tim Raine
Stefanos BonovasStefanos Bonovas
Stefanos Bonovas
JBJohan Burisch
Johan Burisch
TKTorsten Kucharzik
Torsten Kucharzik
MAMichel Adamina
Michel Adamina
GDGlen Doherty
Glen Doherty
Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic inflammation extending to a variable extent from the rectum. Care of the patient with UC requires appropriate input from across the multiprofessional team. These guidelines summarise the recommended medical treatment for adults with UC. Other ECCO guidelines consider the approach to UC diagnosis and monitoring,1–3 nursing care,4 management of disease complications,5–7 risk of infection,8 and technical aspects of surgery.9 This document was prepared as part of a process that also led to the publication of a related guideline with recommendations on the surgical care of the patients with UC and on the medical aspects of the management of the patient hospitalised with severe UC. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment.

18 August 2022 in The Lancet
Verified
Journal Article
Open access
KTKhanh Bao Tran
Khanh Bao Tran
JLJustin J Lang
Justin J Lang
KCKelly Compton
Kelly Compton
RXRixing Xu
Rixing Xu
AAAlistair R Acheson
Alistair R Acheson
CMChristopher J L Murray
Christopher J L Murray
Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk–outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1·84) risk-attributable cancer deaths in females (36·3% [32·5–41·3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the greatest percentage increase in metabolic risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]). The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden. Bill & Melinda Gates Foundation.

7 April 2022 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Open access
RSRajesh Sharma
Rajesh Sharma
MAMohsen Abbasi-Kangevari
Mohsen Abbasi-Kangevari
RARami Abd-Rabu
Rami Abd-Rabu
HAHassan Abidi
Hassan Abidi
EAEman Abu-Gharbieh
Eman Abu-Gharbieh
MZMohammad Zoladl
Mohammad Zoladl
Colorectal cancer is the third leading cause of cancer deaths worldwide. Given the recent increasing trends in colorectal cancer incidence globally, up-to-date information on the colorectal cancer burden could guide screening, early detection, and treatment strategies, and help effectively allocate resources. We examined the temporal patterns of the global, regional, and national burden of colorectal cancer and its risk factors in 204 countries and territories across the past three decades. Estimates of incidence, mortality, and disability-adjusted life years (DALYs) for colorectal cancer were generated as a part of the Global Burden of Diseases, Injuries and Risk Factors Study (GBD) 2019 by age, sex, and geographical location for the period 1990–2019. Mortality estimates were produced using the cause of death ensemble model. We also calculated DALYs attributable to risk factors that had evidence of causation with colorectal cancer. Globally, between 1990 and 2019, colorectal cancer incident cases more than doubled, from 842 098 (95% uncertainty interval [UI] 810 408–868 574) to 2·17 million (2·00–2·34), and deaths increased from 518 126 (493 682–537 877) to 1·09 million (1·02–1·15). The global age-standardised incidence rate increased from 22·2 (95% UI 21·3–23·0) per 100 000 to 26·7 (24·6–28·9) per 100 000, whereas the age-standardised mortality rate decreased from 14·3 (13·5–14·9) per 100 000 to 13·7 (12·6–14·5) per 100 000 and the age-standardised DALY rate decreased from 308·5 (294·7–320·7) per 100 000 to 295·5 (275·2–313·0) per 100 000 from 1990 through 2019. Taiwan (province of China; 62·0 [48·9–80·0] per 100 000), Monaco (60·7 [48·5–73·6] per 100 000), and Andorra (56·6 [42·8–71·9] per 100 000) had the highest age-standardised incidence rates, while Greenland (31·4 [26·0–37·1] per 100 000), Brunei (30·3 [26·6–34·1] per 100 000), and Hungary (28·6 [23·6–34·0] per 100 000) had the highest age-standardised mortality rates. From 1990 through 2019, a substantial rise in incidence rates was observed in younger adults (age <50 years), particularly in high Socio-demographic Index (SDI) countries. Globally, a diet low in milk (15·6%), smoking (13·3%), a diet low in calcium (12·9%), and alcohol use (9·9%) were the main contributors to colorectal cancer DALYs in 2019. The increase in incidence rates in people younger than 50 years requires vigilance from researchers, clinicians, and policy makers and a possible reconsideration of screening guidelines. The fast-rising burden in low SDI and middle SDI countries in Asia and Africa calls for colorectal cancer prevention approaches, greater awareness, and cost-effective screening and therapeutic options in these regions. Bill & Melinda Gates Foundation.

15 June 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
HGHannah Gordon
Hannah Gordon
SMSilvia Minozzi
Silvia Minozzi
Uri KopylovUri Kopylov
Uri Kopylov
BVBram Verstockt
Bram Verstockt
MCMaría Chaparro
María Chaparro
TRTim Raine
Tim Raine
Hannah Gordon, Silvia Minozzi, Uri Kopylov, Bram Verstockt, Maria Chaparro, Christianne Buskens, Janindra Warusavitarne, Manasi Agrawal, Mariangela Allocca

23 June 2023 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
HGHannah Gordon
Hannah Gordon
JBJohan Burisch
Johan Burisch
PEPierre Ellul
Pierre Ellul
KKKonstantinos Karmiris
Konstantinos Karmiris
KKKonstantinos Katsanos
Konstantinos Katsanos
TKTorsten Kucharzik
Torsten Kucharzik
Hannah Gordon, Johan Burisch, Pierre Ellul, Konstantinos Karmiris, Konstantinos Katsanos, Mariangela Allocca, Giorgos Bamias, Manuel Barreiro-de Acosta, Tasanee